The effect of ivabradine on the quality of life in patients with heart failure with reduced ejection fraction

Studying the effect of ivabradine on the quality of life in patients with heart failure with reduced ejection fraction: a double-blind, placebo-controlled randomized clinical trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20250518065795N1

Enrollment

Registered

2025-07-07

Start date

2025-09-11

Completion date

Unknown

Last updated

2025-07-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Heart failure with reduced ejection fraction. Left ventricular failure

Interventions

Intervention 1: The intervention group will receive Ivabradine tablets (5 mg every 12 hours) for one month in addition to their routine treatments to evaluate its effect on their quality of life. Inte

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: A confirmed diagnosis of heart failure with reduced ejection fraction with an ejection fraction of less than 35% Use of the maximum dose of beta-blocker or the maximum tolerated dose Sinus rhythm on electrocardiogram Heart rate above 70 bpm Informed consent for participation in the study At least 18 years old

Exclusion criteria

Exclusion criteria: Not having consent for participation in the study Pregnancy Having any comorbid condition that impairs quality of life

Design outcomes

Primary

Measure	Time frame
Quality of life score. Timepoint: At baseline (before the start of the intervention) and one month after initiation of treatment. Method of measurement: Minnesota Living with Heart Failure Questionnaire (MLHFQ).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Reza Noori

Tabriz University of Medical Sciences

dr.noori_r@yahoo.com+98 41 3337 3900

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026